Skip Navigation

JNCI Journal of the National Cancer Institute 2000 92(9):671; doi:10.1093/jnci/92.9.671
© 2000 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 92, No. 9, 671, May 3, 2000
© 2000 Oxford University Press

IN THIS ISSUE

Advanced Ovarian Cancer and Paclitaxel–Cisplatin Therapy

A previous randomized trial conducted by the Gynecologic Oncology Group in the United States showed a better outcome for patients with advanced ovarian cancer on a paclitaxel–cisplatin regimen compared with those on a standard cyclophosphamide–cisplatin regimen. Before considering the paclitaxel–cisplatin regimen as a new "standard," Piccart et al. (p. 699) planned a confirmatory phase III trial. This new trial observed a higher overall clinical response rate (58.4% versus 44.7%) and a higher complete clinical remission rate (40.7% versus 27.3%) in the paclitaxel group compared with . . . [Full Text of this Article]

Human Papillomaviruses and Head and Neck Cancers

Kaposi’s Sarcoma: Transgenic Mouse Model

HHV8 Sequences in Kaposi’s Sarcoma and Other Diseases

Lung Cancer Risk, Growth Factors, and Genetic Instability


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?